• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Walking Through 'Fire and Ice' for a Cure


A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.

The team trekked to
Skogafoss Waterfall
on day four of the

The team trekked to Skogafoss Waterfall on day four of the adventure. - PHOTO BY UNCAGE THE SOUL PRODUCTIONS

The team trekked to Skogafoss Waterfall on day four of the adventure. - PHOTO BY UNCAGE THE SOUL PRODUCTIONS

TOM SEIDELL WAS SHOCKED when he learned that his mother, Cathy, had multiple myeloma — he had never before heard of that type of cancer. It was 2011, and he was just starting his first job out of school. His twin sisters were in college. The three felt helpless.

Then Liz, one of the twins, found out about the Multiple Myeloma Research Foundation (MMRF). She, Seidell and their sister, Erica, began participating in half-marathons to raise money for research. “It was our way of having some sort of fight alongside our mom,” says Seidell, now 31.

Following a stem cell transplant in 2011, his mother went into remission and was soon back to work, but in late 2016 her disease came back. In January 2017, she lost her fight with multiple myeloma. “She always had the most positive outlook on everything throughout her entire battle,” Seidell says. On Aug. 8 to 12, during the week of what would have been his mother’s 67th birthday, Seidell and 15 others hiked what is known as Fire and Ice, a trek in Iceland.

The team consisted of five patients, Rich Appelbaum, Barbara McCarrick, Jen Phlieger Ansier, Emily Schottman and Brian Smith; seven caregivers, Erin Calufetti- Schumacher, Alex Cavin, Mary Gilbride, Erica Harrison, Jane Hoffman, Tina Mattis and Seidell; a myeloma doctor, Cesar Rodriguez, M.D.; Marty Murphy, director of patient education for CURE Media Group; and John Waller and Ben Canales of Uncage the Soul Video Production.

Known for its dramatic landscape, Iceland boasts volcanoes, geysers, hot springs and lava fields, as well as massive glaciers that are protected in national parks. The Iceland trek is the ninth endurance event hosted by Moving Mountains for Multiple Myeloma, a collaboration between CURE Media Group and MMRF and sponsored by Celgene to raise awareness and funds for myeloma research. The team has raised $135,000 so far, already exceeding the goal of $120,000.

“There is a certain magic that happens when you bring together 16 strangers all bound by a common connection to myeloma,” says Alicia O’Neill, director of partnerships and business development for MMRF. “When they go through the experience of pushing their limits and pushing (toward) a common goal, they become vulnerable, and our humanity shines through.”


The five-day trip consisted of three days of hiking nearly eight hours a day and then taking shelter in mountain huts overnight. The most physically challenging part of the hike was a long, narrow ridge known as the Cat’s Spine. “The will to achieve the goal of getting to the summit, to getting through this together, is a not only a metaphor for overcoming cancer but (also) is a powerful experience that helps patients show themselves — and the world — that they can go back to the days before they were diagnosed. And they can actually live their dreams,” says O’Neill.

Since 2016, Moving Mountains for Multiple Myeloma teams have taken on Mount Kilimanjaro twice; multiple treks in the Grand Canyon, including Havasu Falls; Machu Picchu; Mount Fuji; and base camp at Mount Everest.

These adventures have brought in more than $2 million — all collected through fundraising completed by each member of the team.

“Even though my mom has passed, I still want to stay involved,” Seidell says. “I still want to do what I can to contribute to ending this disease for families like ours and families of the people who I have met on this team and who continue to inspire me.”

Although a relatively uncommon cancer, multiple myeloma is the second most common blood cancer. More than 30,000 cases will be diagnosed this year in the United States, affecting more men than women. Despite many breakthroughs in treatment, there is still no cure.

Over the past 20 years, the MMRF has funded more than $400 million in myeloma research. The foundation works with 25 centers of excellence throughout the world, including Dana-Farber Cancer Institute in Boston and Memorial Sloan Kettering Cancer Center in New York City. “When we fund this research, it is with the stipulation that all of our researchers must collaborate, must fill the clinical trials quickly and must share the findings with other researchers worldwide,” O’Neill says.

In the past 11 years, the Food and Drug Administration has approved 10 anticancer drugs to treat multiple myeloma — that’s the amount of time it usually takes for one new drug to come to market, according to O’Neill.

“The life expectancy of a patient with myeloma has tripled in the last 10 years,” she says.

Known as the Cat's Spine (left), team members crossed the narrow, uneven passage on day two of the trek. On the same day, the
team also hiked through snow (right) pulling out gloves and hats from their backpacks. - PHOTOS BY MARTY MURPHY

Known as the Cat's Spine (left), team members crossed the narrow, uneven passage on day two of the trek. On the same day, the team also hiked through snow (right) pulling out gloves and hats from their backpacks. - PHOTOS BY MARTY MURPHY

Known as the Cat's Spine (left), team members crossed the narrow, uneven passage on day two of the trek. On the same day, the team also hiked through snow (right) pulling out gloves and hats from their backpacks. - PHOTOS BY MARTY MURPHY


O’Neill anticipates that two more new therapies will be approved in the next 12 to 18 months. “There is life beyond diagnosis,” she says. “There is a lot of living to do. We can all be a part of the action that is driving this research.”

To prepare for the Iceland terrain, the team participated in a practice hike in North Carolina three months prior and also trained on their own.

Phlieger Ansier and Schottman, who both live in Austin, Texas, trained together in hilly local neighborhoods. The two met in a coffee shop seven years ago, when Phlieger Ansier shared her wigs with Schottman. Both women received a diagnosis of multiple myeloma when they were in their 30s, much younger than the average age of diagnosis — 65 years old.

Phlieger Ansier had just turned 31. During an annual wellness exam, her doctor recommended getting her cholesterol checked. Those results turned out fine, but others didn’t. A few more doctors and an oncologist later, her cancer was revealed. “The oncologist came out and said, ‘Your numbers really caught my attention,’ which you never want to hear from a doctor. You want to be the most boring person ever,” Phlieger Ansier says. “It’s a sobering realization that you may not make it to 40.”

Twelve years later, she lives life to the fullest, traveling often. She goes for bloodwork every four months. The Iceland trek pushed her out of her comfort zone, she says, but also has been therapeutic. “Because I’m not that active of a person, it’s showing people that you can do what you think you can’t,” she says. “You can always push yourself. You can hope to inspire others by doing something that you normally wouldn’t do.”

McCarrick agrees. The 59-year-old, who joined the team and supports the MMRF to inspire and raise awareness, says she was in disbelief after being told she had multiple myeloma in 2009.

Ironically, McCarrick, an occupational therapist who lives in Pleasanton, California, had worked with patients with multiple myeloma. After her diagnosis, she immediately began radiation and chemotherapy, then underwent a stem cell transplant later that year. In early 2010, she was in complete remission. However, she relapsed in 2013 and went back on chemotherapy — Revlimid (lenalidomide), an oral drug, and subcutaneous Velcade (bortezomib).

Since January 2014, she has been in remission, with no maintenance medication.

Although she had been involved with the MMRF since her diagnosis, McCarrick was not aware of the endurance events hosted until she stumbled across an article in CURE® while sitting in an oncologist’s office with her brother, who was being treated for lung cancer. Shortly after that, she received an email from the MMRF. “I didn’t have to search it out. It came to me,” she says. “So I said, ‘Yes, absolutely, this is what I’m going to do.’”

She wants others, whether they are fighting multiple myeloma or any type of cancer, to know that seeking support is not a sign of weakness. “Life can be pretty darn positive with cancer,” McCarrick says. “People will say, ‘You’re so strong.’ If it happened to you, you would step up and do the same. You find that inner strength that you didn’t know you had.”

Patients commonly fear recurrence, but McCarrick chooses to focus on living a healthier lifestyle in hopes of lowering her risk of relapse. Phlieger Ansier said the disease has changed her outlook forever, too: “Life is too short to always do the practical thing.”

For Seidell, his mother’s legacy lives on through his family and its newest addition — his niece Libby, who turned 1 year old in September. The little girl bears his mother’s maiden name. “My sister found out she was pregnant shortly after my mom passed,” Seidell says. “It’s bittersweet, but also pretty amazing.”

Related Videos
Dr. Mikhael in an interview with CURE
Dr. Ajai Chari in an in interview with CURE
An image of Dr. Patel in an interview with CURE discussing healthy lifestyles in myeloma
Dr. Munshi in an interview with CURE
Dr. Dikran Kazandjian during an interview with CURE
Looking Ahead Panel
Related Content